Clinical Trials Browser

Rectal Neoplasms

Gastric Adenocarcinoma

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Muscle Invasive Bladder Cancer (MIBC)

HER2-low Breast Cancer

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

HER2-positive Gastric Cancer

Stomach Neoplasms

Lung Neoplasms

Prostatic Neoplasms

Ovarian Cancer Recurrent

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Stomach Neoplasms

Non-Muscle Invasive Bladder Neoplasms

HER2-positive Gastric Cancer

Stomach Neoplasms

Pancreatic Neoplasms

HER2-positive Metastatic Breast Cancer

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Stomach Neoplasms

Muscle Invasive Bladder Carcinoma

Non-Muscle Invasive Bladder Neoplasms

Muscle Invasive Bladder Cancer

Breast Neoplasms

Breast Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Breast Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Urinary Bladder Neoplasms

Colorectal Neoplasms

Urinary Bladder Neoplasms

Clinical Trials

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

DTP-HER2

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

BRIGHT

RC48-ADC in HER2-low Advanced Breast Cancer

Disitamab Vedotin (RC48-ADC) in Breast Cancer

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

DECIDING

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

DAB

DIVON

Neoadjuvant Therapy in Cervical Cancer

RCTS

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

DETECT

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer